All In Biotech

Drug Trial Radar · NCT07743983

A Study of BGM0504 in Early T2DM With Obesity

A Randomized, Open-Label, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety, and Diabetes Remission of BGM0504 Injection Compared With Semaglutide Injection in Early-Stage Chinese Type 2 Diabetes Mellitus Patients With Obesity and Inadequate Glycemic and Weight Control Despite Diet and Exercise Intervention(BRIGHT-1)

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 372 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

372

Planned (sponsor's estimate)

Start

Sep 17, 2026

Primary completion

Sep 30, 2028

Study completion Nov 30, 2028

Sponsor

Sponsor type
Industry
First posted
Aug 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in China. The aim is to compare BGM0504 Injection 15 mg with semaglutide 1.0 mg in Chinese T2DM patients with obesity and inadequate control despite diet and exercise. Over 52 weeks of once weekly treatment, efficacy and safety are evaluated, including the rate of diabetes remission at 12 weeks after treatment discontinuation.

Conditions

  • Type 2 Diabetes (T2DM)

Interventions

  • BGM0504Drug

    Administered as a subcutaneous injection once weekly for 52 weeks.

  • semaglutideDrug

    Administered as a subcutaneous injection once weekly for 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants Achieving HbA1c < 7.0% and Body Weight Reduction ≥ 10% from BaselineTime frame: Week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanjing Drum Tower Hospital(The Affiliated Hospital of Nanjing University Medical School)

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.